Response fluctuations in Parkinson's disease
- PMID: 2392214
- DOI: 10.1212/wnl.40.9.1344
Response fluctuations in Parkinson's disease
Abstract
We studied the influence of several factors on the occurrence of response fluctuations in 91 Parkinson's disease patients. These included the age at onset, the presenting symptom, the duration of illness, and the stage of the disease at the time of initiation of levodopa treatment as time-independent covariates, and the mean and last dosage of levodopa as time-dependent covariates. Taken separately, none of the factors was related to the occurrence of response fluctuations. We found no evidence to delay levodopa treatment to a later stage of the disease. In the analysis of the combined influence of the age at onset and the interval before levodopa treatment, we noted a tendency for response fluctuations to occur less frequently in those patients with age at onset of 60 years and over who had started levodopa treatment more than 2 years after the 1st symptom. Our analysis of the combination of time-dependent factors suggests that response fluctuations are a likely event in those patients in whom the course of the disease recently necessitated an increase in the dosage of levodopa.
Similar articles
-
Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease.J Neural Transm Park Dis Dement Sect. 1993;5(2):127-33. doi: 10.1007/BF02251203. J Neural Transm Park Dis Dement Sect. 1993. PMID: 8333908
-
[Motor fluctuations in Parkinson disease: risk factors].Neurologia. 1992 May;7(5):89-93. Neurologia. 1992. PMID: 1389297 Spanish.
-
Factors that influence the occurrence of response variations in Parkinson's disease.Ann Neurol. 1987 Jul;22(1):4-7. doi: 10.1002/ana.410220104. Ann Neurol. 1987. PMID: 3631919
-
Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.CNS Drugs. 2003;17(7):475-89. doi: 10.2165/00023210-200317070-00002. CNS Drugs. 2003. PMID: 12751918 Review.
-
When do levodopa motor fluctuations first appear in Parkinson's disease?Eur Neurol. 2010;63(5):257-66. doi: 10.1159/000300647. Epub 2010 Mar 24. Eur Neurol. 2010. PMID: 20332641 Review.
Cited by
-
Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?Drug Saf. 1999 Nov;21(5):339-52. doi: 10.2165/00002018-199921050-00001. Drug Saf. 1999. PMID: 10554050 Review.
-
Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs.J Neural Transm (Vienna). 1996;103(3):343-8. doi: 10.1007/BF01271245. J Neural Transm (Vienna). 1996. PMID: 8739845
-
Clinical pharmacology of dopamine agonists in Parkinson's disease.Drugs Aging. 1998 Nov;13(5):381-9. doi: 10.2165/00002512-199813050-00004. Drugs Aging. 1998. PMID: 9829165 Review.
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
-
Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.Curr Treat Options Neurol. 2001 Nov;3(6):479-493. doi: 10.1007/s11940-001-0011-z. Curr Treat Options Neurol. 2001. PMID: 11581525
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical